ArticleNeuropsychiatric disease and treatment2011
Risk factors for the development of depression in patients with hepatitis C taking interferon-α.
Article in Neuropsychiatric disease and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Effect of immune activation on the kynurenine pathway and depression symptoms - A systematic review and meta-analysis.Neuroscience and biobehavioral reviews · 2020Pooled it
- Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy.PloS one · 2012Trial
- Sociodemographic Risk Factors for Depression in Patients With Chronic Liver Disease.Clinical liver disease · 2022Review
- Moderators of inflammation-related depression: a prospective study of breast cancer survivors.Translational psychiatry · 2021Article
- Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.International journal of psychiatry in medicine · 2018Article
- CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.Immunotherapy · 2017Review
- Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-α and Ribavirin Treatment in Chronic Hepatitis Patients.Archivum immunologiae et therapiae experimentalis · 2016Article
- A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz.Hepatitis monthly · 2016Article
- Self-reference in psychosis and depression: a language marker of illness.Psychological medicine · 2016Article
- Minocycline attenuates interferon-α-induced impairments in rat fear extinction.Journal of neuroinflammation · 2016Article
- The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2016Article
- Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS).Hepatology (Baltimore, Md.) · 2015Article
- An Exploration of Depressive Symptoms in Hepatitis C Patients Taking Interferon-alpha: Increase in Sickness Behaviors but not Negative Cognitions.Journal of clinical and experimental hepatology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-α, currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However, not everyone who takes this drug becomes depressed, so it is important to understand what particular factors may make some individuals more 'at risk' of developing depression than others. Currently there is no consensus as to why interferon-induced depression occurs and the range of putative risk factors is wide and diverse. The identification of risk factors prior to treatment may allow identification of patients who will become depressed on interferon, allowing the possibility of improved treatment support and rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and we discuss the potential confounds within the research examined in order to better isolate the risk factors that may be important in the development of depression in these patients and which might help predict patients likely to become depressed on treatment. We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis C taking interferon-α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.